08:42 AM EDT, 10/21/2024 (MT Newswires) -- BeiGene ( BGNE ) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending an extended authorization for Tevimbra (tislelizumab) in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

The recommendations were based on two clinical trials showing that the drug, in combination with chemotherapy, "improved survival compared to treatment with a placebo plus chemotherapy," said Florian Lordick, director and professor of oncology at the University Cancer Center in Leipzig.

BeiGene ( BGNE ) shares were 0.5% higher in recent premarket trading.

Price: 220.00, Change: +1.03, Percent Change: +0.47